Mannkind Corp

NASDAQ:MNKD   3:59:58 PM EDT
4.02
-0.08 (-1.95%)
Products, Other Pre-Announcement

United Therapeutics Announces FDA Acceptance Of Tyvaso Dpi™ New Drug Application For Priority Review

Published: 06/16/2021 10:36 GMT
Mannkind Corp (MNKD) - United Therapeutics Announces FDA Acceptance of Tyvaso Dpi™ New Drug Application for Priority Review.
United Therapeutics Corp - Expects Agency's Review to Be Complete in October 2021.
United Therapeutics - FDA Indicated Approval of NDA Will Be Subject to Inspection of Tyvaso Dpi Manufacturing Facility Operated by Mannkind Corp.
United Therapeutics - FDA and Mannkind Have Jointly Targeted Q3 of 2021 to Complete Inspection.